Natriuretic peptide receptor 1 antibodies and methods of use
This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
1. An isolated anti-natriuretic peptide receptor 1 (NPR1) antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) selected from:
(I) SEQ ID NO: 28 (HCDR1), SEQ ID NO: 119 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 41 (LCDR1), SEQ ID NO: 42 (LCDR2), and SEQ ID NO: 134 (LCDR3);
(II) SEQ ID NO: 31 (HCDR1), SEQ ID NO: 119 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 41 (LCDR1), SEQ ID NO: 42 (LCDR2), and SEQ ID NO: 134 (LCDR3);
(III) SEQ ID NO: 32 (HCDR1), SEQ ID NO: 120 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 44 (LCDR1), SEQ ID NO: 45 (LCDR2), and SEQ ID NO: 135 (LCDR3); and
(IV) SEQ ID NO: 34 (HCDR1), SEQ ID NO: 121 (HCDR2), SEQ ID NO: 36 (HCDR3), SEQ ID NO: 47 (LCDR1), SEQ ID NO: 45 (LCDR2), and SEQ ID NO: 134 (LCDR3).
2. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises:
(a) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 201, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 136; or
(b) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 122, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 136.
3. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises:
(a) a heavy chain comprising an amino acid sequence of SEQ ID NO: 203, and a light chain comprising an amino acid sequence of SEQ ID NO: 138; or
(b) a heavy chain comprising an amino acid sequence of SEQ ID NO: 208, and a light chain comprising an amino acid sequence of SEQ ID NO: 138.
4. The antibody or antigen binding fragment of claim 1 , which is an antigen binding fragment selected from the group consisting of a Fab, Fab′, F(ab′) 2 , Fv, and a single chain variable fragment (scFv).
5. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is therapeutic.
6. A pharmaceutical composition comprising an antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , wherein the composition further comprises an additional therapeutic agent.
8. The pharmaceutical composition of claim 7 , wherein the additional therapeutic agent is selected from an ACE (angiotensin-converting-enzyme) inhibitor, an angiotensin receptor blocker (ARB), a neprily sin inhibitor, a beta blocker, a diuretic, a calcium channel blocker, a cardiac glycoside, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), an angiotensin receptor-neprilysin inhibitor (ARNi), a corticosteroid, a leukotriene modifier, a bronchodilator, a beta-adrenoceptor antagonist, a carbonic anhydrase inhibitor, an alpha 2-adrenoceptor agonist, a parasympathomimetic, a prostaglandin analog, a rho kinase inhibitor, and combinations thereof.
9. The pharmaceutical composition of claim 7 , wherein the additional therapeutic agent is selected from enalapril, benazepril, captopril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, valsartan, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, sacubitril, bisoprolol, carvedilol, propanolol, metoprolol, metoprolol tartrate, metoprolol succinate, thiazide diuretics, loop diuretics, potassium-sparing diuretics, amlodipine, clevidipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil, a digitalis glycoside, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metolazone, bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, eplerenone, spironolactonem, triamterene, digoxin, fluticasone, budesonide, mometasone, beclomethasone, ciclesonide, fluticasone furoate, prednisone, methylprednisolone, montelukast, zafirlukast, zileuton, a long-acting beta agonist, a short-acting beta agonist, theophylline, ipratropium, salmeterol, formoterol, albuterol, levalbuterol, timolol, levobunolol, metipranolol, carteolol, betaxolol, acetazolamide, dorzolamide, brinzolamide, methazolamide, brimonidine, apraclonidine, a cholinomimetic, latanoprost, latanoprostene bunod, travoprost, bimatoprost, tafluprost, netarsudil, ripasudil, and combinations thereof.
10. A method of treating a cardiovascular disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the antibody or antigen binding fragment of claim 1 .
11. The method of claim 10 , wherein the cardiovascular disorder is selected from: hypertension, peripheral vascular disease, heart failure, coronary artery disease (CAD), ischemic heart disease (IHD), mitral stenosis and regurgitation, angina, hypertrophic cardiomyopathy, diabetic cardiomyopathy, supraventricular and ventricular arrhythmias, cardiac dysrhythmia, atrial fibrillation (AF), new onset of atrial fibrillation, recurrent atrial fibrillation, cardiac fibrosis, atrial flutter, detrimental vascular remodeling, plaque stabilization, and myocardial infarction (MI).
12. The method of claim 11 , wherein the subject has heart failure, and wherein the heart failure is selected from a heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), heart failure after acute myocardial infarct, or acute decompensated heart failure.
13. The method of claim 11 , wherein the subject has hypertrophic cardiomyopathy, and wherein the hypertrophic cardiomyopathy is ventricular hypertrophy.
14. The method of claim 11 , wherein the subject has hypertension, and wherein the hypertension is selected from resistant hypertension, hypertensive heart disease, pulmonary hypertension, pulmonary arterial hypertension, isolated systolic hypertension, resistant hypertension, and pulmonary arterial hypertension.
15. The method of claim 11 , wherein the subject has hypertension, and wherein the hypertension is selected from resistant hypertension or hypertensive heart disease.
16. A method of treating a kidney disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the antibody or antigen binding fragment of claim 1 .
17. The method of claim 16 , wherein the kidney disorder is selected from: diabetic renal insufficiency, non-diabetic renal insufficiency, renal failure, diabetic nephropathy, non-diabetic nephropathy, acute renal injury, contrast induced nephropathy, nephrotic syndrome, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, renal vascular hypertension, diabetic retinopathy and end-stage renal disease (ESRD), endothelial dysfunction, diastolic dysfunction, renal fibrosis, and polycystic kidney disease (PKD).